| 2007-12-19: |
Avastin Approved in Europe for First - Line Treatment of Patients With Advanced Kidney Cancer
Basel ( PRN/ots ) - - Avastin Offers Patients the Chance to Live Twice as Long Without Their Disease Advancing Avastin ( bevacizumab ), Roche's innovative anti - cancer drug, was approved today in Europe for the first - line treatment of patients with advanced renal cell cancer ( RCC ) (...) |
| 2007-12-17: |
Vasogen and Grupo Ferrer Announce Initial Roll - out of Celacade - New Therapy for Chronic Heart Failure
Mississauga, Canada ( PRN/ots ) - Vasogen Inc. ( NASDAQ:VSGN; TSX:VAS ) and Grupo Ferrer Internacional, S.A. ( "Ferrer" ), a leading European pharmaceutical and medical devices company, today announced the receipt of initial orders for Vasogen's Celacade( TM ) System in Germany. Celacade, a first - in - class therapy, is (...) |
| 2007-12-17: |
Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
San Antonio, Texas ( PRN/ots ) - - Roche in Collaboration With Genentech Commit to Large Phase III Adjuvant Clinical Programme Set to Unlock Avastin's Potential in Early Breast Cancer According to new phase II study data, Avastin ( bevacizumab ) can proceed to be tested after (...) |
| 2007-12-15: |
Addition of Xeloda to Herceptin and Docetaxel Allows Patients With Breast Cancer to Live Five Months Longer Without Their Cancer Growing
San Antonio, Texas ( PRN/ots ) - New data presented today at the San Antonio Breast Cancer Symposium ( SABCS ) show that adding Xeloda ( capecitabine ) to the current gold standard combination of Herceptin ( trastuzumab ) and docetaxel allows patients with advanced HER2 - positive breast cancer to live, on (...) |
| 2007-12-14: |
MabThera Receives Positive Opinion in Europe for Combination With Any Chemotherapy Regimen in First - Line Treatment for Follicular Non - Hodgkin's Lymphoma
Basel, Switzerland ( PRN/ots ) - - Physicians Will be Able to Prescribe MabThera With Their Preferred Chemotherapy Regimen as Initial Treatment Roche announced today that the European Union's Committee on Human Medical Products ( CHMP ) has given a positive recommendation for extension of the MabThera (...) |
| 2007-12-14: |
Avastin and Xeloda Receive Positive Recommendations for Label Extensions in Europe for Treatment of Advanced Colorectal Cancer
Basel, Switzerland ( PRN/ots ) - Roche has received positive recommendations for the Marketing Authorisation extensions for both its anti - angiogenic agent Avastin ( bevacizumab ) and oral chemotherapy Xeloda ( capecitabine ) from the European Committee for Medicinal Products for Human Use ( CHMP ). The recommendation for the extended label of (...) |
| 2007-12-13: |
New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia
Malvern, Pennsylvania ( PRN/ots ) - - Solstice Neurosciences, Inc. Launches a Self - Guided Lesson as Prep for In - Person Workshops In recognition that physician comfort and knowledge with techniques around botulinum toxin injections lead to the best results for patients with cervical dystonia ( CD ), (...) |
| 2007-12-11: |
MabThera Improves Response in Patients With Most Common Form of Adult Leukaemia
Basel, Switzerland ( PRN/ots ) - - Higher Response Rates Seen in Untreated and Relapsed CLL Patients For non - US media only Abstract Number: 626 Abstract Number: 752 Early results from two phase II trials tracking the outcome of patients with chronic lymphocytic leukaemia (...) |
| 2007-12-10: |
FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX - 208
Calgary, Canada ( PRN/ots ) - - New Class of ApoA - I/HDL Drugs to Reverse Atherosclerosis Enters the Clinic Resverlogix Corp. ( "Resverlogix" ) ( TSX:RVX ) announced today that it has received approval by the US Food and Drug Administration ( FDA ) to initiate a Phase 1a (...) |
| 2007-12-05: |
New Data Reinforces the Superiority of Escitalopram Over Duloxetine for Acute Treatment of Depression
Copenhagen ( PRN/ots ) - - Attention Medical Trade Press Only - Further Study Demonstrates Efficacy and Tolerability of Escitalopram in Premenstrual Dysphoric Disorder New data released today reinforces the superiority of escitalopram compared to duloxetine in the acute treatment of depression and provides a further (...) |
| 2007-12-04: |
International Day of Disabled Persons
Toronto ( PRN/ots ) - "Governments need to recognize the rights and needs of people with disabilities," says Prof. Allen Foster, President of CBM on the International Day of Disabled Persons. Millennium Development Goals set out by the United Nations will not be achieved (...) |
| 2007-11-29: |
Resverlogix Honoured With World Economic Forum Technology Pioneer Award
Calgary, Canada, November 29 ( PRN/ots ) - - ApoA - I Technology is Recognized for its Ability to Transform the Treatment of Cardiovascular Disease Resverlogix Corp. ( "Resverlogix" ) ( TSX:RVX ) is pleased to announce today that the World Economic Forum has selected Resverlogix as a winner (...) |
| 2007-11-29: |
First European Patient Treated in CABERNET Trial with Novel Treatment for Wet AMD
Leipzig, Germany, November 29 ( PRN/ots ) - - Ophthalmic Clinic in Germany First in Europe To Treat Patients With New Focused Radiation Therapy NeoVista, Inc. announced today that the first European patient has been treated in the company's pivotal global clinical trial for (...) |
| 2007-11-26: |
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
Collegeville, Pennsylvania, November 26 ( PRN/ots ) - - TORISEL Extends Median Overall Survival vs. Interferon - Alpha Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announced today that the European Commission has approved TORISEL( TM ) ( temsirolimus ) for the first - line treatment of patients with advanced renal (...) |
| 2007-11-22: |
Bangladesh Cries for our Help
Toronto, November 22 ( PRN/ots ) - "CBM urgently needs help for the most vulnerable people affected by the recent flooding in Bangladesh," says Prof. Allen Foster President of CBM. The latest report says the death toll in the fiercest cyclone to hit Bangladesh's (...) |
| 2007-11-20: |
Review Publication Confirms the Benefits of Highly Effective Oral Cancer Drug Xeloda( R ) ( capecitabine ) Over Intravenous Chemotherapy in Advanced Breast Cancer
Basel, Switzerland, November 20 ( PRN/ots ) - - Annals of Oncology Paper Suggests That Oral Agents Such as Xeloda, Which are Proven to be Equally Effective and Have a Tolerable Side Effect Profile, Should Replace Traditional Intravenous Chemotherapy A review paper in Annals of (...) |
| 2007-11-19: |
Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study
Amsterdam, November 19 ( PRN/ots ) - Kiadis Pharma announced today that it has agreed to provide Rhitol during a limited period of time to requesting physicians participating in the ongoing phase I/II trial. The Rhitol phase I/II trial is closed for enrolment (...) |
| 2007-11-16: |
Avastin Receives Positive Opinion in Europe for First - Line Treatment of Patients With Advanced Kidney Cancer
Basel, Switzerland, November 16 ( PRN/ots ) - - Avastin Offers Patients the Chance to Live Twice as Long Without Their Disease Advancing Roche announced today that the European Committee for Medicinal Products for Human Use ( CHMP ) has issued a positive recommendation for Avastin ( bevacizumab ) (...) |
| 2007-11-15: |
EFIC - Grunenthal Grant 2007: The new generation of pain researchers
Aachen, Germany ( na Originaltextservice ) - - Cross reference: Picture is available at http://www.presseportal.de/galerie.htx?type=obs - Today the European Federation of Chapters of the International Association for the Study of Pain ( EFIC ) and the pharmaceutical company Grunenthal GmbH award five (...) |
| 2007-11-14: |
Gates Foundation Commits to Expansion of HIV Prevention in China
Seattle, November 14 ( PRN/ots ) - - New initiative to support prevention programs targeting high - risk groups The Bill & Melinda Gates Foundation announced today that it will commit US$50 million to work in partnership with the Chinese government and non - governmental organizations to (...) |
| 2007-11-08: |
Pieris strengthens its management, as it prepares for the clinical development of PRS - 050, an Anticalin® - based novel cancer therapy
Freising - Weihenstephan ( na Originaltextservice ) - Pieris AG, a biopharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced the appointment of Dr Angelika Stern as Chief Operating Officer to the Company. Pieris has also announced the promotion with (...) |
| 2007-11-08: |
Study Finds New Version of QIAGEN's HPV Test for Developing Countries Could Reduce Risk of Cervical Cancer by More than Half When Combined With Appropriate Treatment
Beijing, November 8 ( PRN/ots ) - - Research Shows the New Test is Accurate, Simple to Run and Requires Minimal Resources Research demonstrating the potential of a special type of HPV test developed by QIAGEN with support from PATH - - a non - profit global health (...) |
| 2007-11-07: |
Fenofibrate - First Lipid Modifying Agent Shown to Protect Diabetic Eye
Sydney, November 7 ( PRN/ots ) - In the Lancet, on Tuesday November, 6th new results of the Fenofibrate Intervention and Event Lowering in Diabetes ( FIELD ) 2007 clinical trial have been published and presented on the same date at a press conference held during the AHA. - (...) |
| 2007-11-06: |
Shire Announces Results of FOSRENOL( R ) Study in Pre - Dialysis CKD Stage 3 & 4 Patients
Philadelphia and Basingstoke, England, November 6 ( PRN/ots ) - Shire plc ( LSE: SHP, NASDAQ: SHPGY, TSX: SHQ ) today announced the results of a Phase II study indicating that FOSRENOL can effectively reduce serum phosphate levels in chronic kidney disease ( CKD ) patients not on dialysis.( 1 ) (...) |
| 2007-11-06: |
Fenofibrate - First Lipid Modifying Agent Shown to Protect Diabetic Eye
Sydney, November 6 ( PRN/ots ) - - First Lipid Modifying Agent Shown to Reduce Risk of Leading Causes of Blindness and Deteriorating Vision in Patients With Type 2 Diabetes - Reduces Need for Laser Treatment in Patients With and Without Known Diabetic Retinopathy - Significantly Decreases (...) |
| 2007-11-05: |
Reverse Cholesterol Transport by RVX - 208 a Small Molecule for ApoA - I Production Increase Presented at American Heart Association Scientific Meeting
Orlando, Florida, November 5 ( PRN/ots ) - Resverlogix Corp. ( "Resverlogix" ) ( TSX:RVX ) is pleased to announce today key scientific data was presented in an oral presentation highlighting the novel features of RVX - 208, at the American Heart Association Scientific Meetings. The presentation titled "Oral Administration (...) |
| 2007-11-05: |
Mircera( R ) Shown to be Effective Anaemia Treatment for Renal Patients With Low Haemoglobin Levels
Basel, Switzerland, November 5 ( PRN/ots ) - - Low Haemoglobin Levels Associated With Increased Risk of Cardiovascular Disease and Death Data from the analysis of six major trials for the innovative new renal anaemia treatment MIRCERA, have shown that it effectively corrects and maintains (...) |
| 2007-11-04: |
Daiichi Sankyo, Lilly Announce New Prasugrel Head - to - Head Phase III Study Against Clopidogrel
Tokyo and Indianapolis, November 4 ( PRN/ots ) - - Duke Clinical Research Institute to lead multinational study with investigational compound; will include 10,000 medically managed patients with acute coronary syndrome A large Phase III clinical trial is anticipated to begin in the second quarter (...) |
| 2007-11-04: |
In Landmark Phase III Head - to - Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
Tokyo and Indianapolis, November 4 ( PRN/ots ) - - Investigational compound reduces risk of major cardiovascular events by 19 percent, significantly improves net clinical benefit despite increased bleeding In the pivotal Phase III head - to - head TRITON TIMI - 38 clinical trial, the investigational antiplatelet (...) |
| 2007-11-02: |
Treatment With PEGASYS/COPEGUS Gives Hepatitis C Patients a Second Chance to Achieve a Cure After Not Responding to PegIntron
Boston, November 2 ( PRN/ots ) - - This Landmark Study Also Shows Response at 12 Weeks is a Powerful Predictor of Eventual Treatment Success. Roche today announced final results from the REPEAT study, which demonstrate that treatment with once - weekly PEGASYS( R ) ( peginterferon alfa - 2a( 40KD ) ) (...) |
| 2007-11-02: |
Roche's Oral Polymerase Inhibitor Shows Robust Antiviral Efficacy in Treatment of Chronic Hepatitis C
Basel, Switzerland, November 2 ( PRN/ots ) - - Roche Progresses R1626 Into Phase IIb Study Called POLI 1 R1626, one of Roche's new investigational drugs for hepatitis C ( HCV ), has shown promising antiviral efficacy when given in combination with PEGASYS( R ) ( peginterferon alfa - 2a (...) |
| 2007-10-31: |
Breaking News About Treatment of World's Leading Cause of Adult Blindness to be Published Next Week
Brussels ( PRN/ots ) - First study to investigate the protective effect of a lipid - lowering agent on diabetic eye disease to be published on - line in Lancet, Tuesday, 6th November 2007 Diabetic eye disease ( called diabetic retinopathy ) is the leading cause of vision loss (...) |
| 2007-10-30: |
New Data Presented at UEGW Confirm Effectiveness and Safety of RESOLOR( R ) for Patients With Chronic Constipation
Paris ( PRN/ots ) - - Novel Compound Offers Hope to Patients not Adequately Responding to Laxative Treatment Data presented for the first time today at the international gastroenterology meeting UEGW ( United European Gastroenterology Week ) confirm the effectiveness and safety of RESOLOR( R ) ( prucalopride ), a novel and (...) |
| 2007-10-30: |
Pieris and Pepscan to identify GPCR - specific Anticalins® using CLIPS[TM] protein mimicry technology
Freising ( na Originaltextservice ) - Pieris AG ( Munich, Germany ) and Pepscan Therapeutics ( Lelystad, Netherlands ) today announced the commencement of a research collaboration aimed at identifying Anticalins® specific for G - Protein Coupled Receptors ( GPCRs ) and their development as therapeutic candidates. Pieris has pioneered Anticalins® as next (...) |
| 2007-10-30: |
Organon Signs an Exclusive, Worldwide Licence Agreement on Advanced Antithrombotic Compounds With Endotis Pharma
Oss, The Netherlands ( PRN/ots ) - Organon, the human healthcare business unit of Akzo Nobel, today announced that it has signed an exclusive, worldwide license agreement with Endotis Pharma concerning the development and commercialization of several antithrombotic compounds. Endotis is a specialty pharma company dedicated to (...) |
| 2007-10-29: |
Study Shows Subcutaneous Injection With MIRCERA is Significantly Less Painful Than With SC Aranesp
Basel, Switzerland ( PRN/ots ) - A new study on pain published today has found that subcutaneous ( SC ) injections of the new renal anaemia therapy MIRCERA is associated with significantly less pain immediately after injection than SC darbepoetin - alfa ( Aranesp ).( 1 ) These findings are important because to (...) |
| 2007-10-25: |
New Three - Year Data Confirms Aptivus( R ) ( tipranavir ) as Effective and Durable Treatment Option for Treatment - Experienced Patients
Madrid, Spain ( PRN/ots ) - - For Non - U.S. Media New data from the combined RESIST studies ( RESIST - 1 and RESIST - 2 ) show that Aptivus( R ) ( tipranavir ), used with Norvir ( ritonavir ), provides a superior and durable treatment response for up to three years in treatment - (...) |
| 2007-10-23: |
Two New Studies Provide Real World Data on Cardiovascular Events in CRESTOR Users
London ( PRN/ots ) - Data from two observational studies of over 470,000 patients taking statins in routine clinical practice investigating the incidence of cardiovascular events in patients taking CRESTOR( TM ) ( rosuvastatin ) and other statins were presented today at the International Society for Pharmacoeconomics and Outcomes Research ( ISPOR ) (...) |
| 2007-10-22: |
Plavix( R ) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
Paris ( PRN/ots ) - Sanofi - aventis announced today that the Japanese Ministry of Health, Labor and Welfare ( MHLW ) has granted approval for a Supplemental New Drug Application ( sNDA ) for the indication of "Acute coronary syndrome ( unstable angina pectoris, non - ST elevation myocardial infarction ) for (...) |
| 2007-10-19: |
Pivotal MIRCERA Study First to Convert Dialysis Patients From Frequent Dosing Directly to Once Every Four Weeks
Basel, Switzerland ( PRN/ots ) - - MAXIMA Findings in the Lancet Affirm Ability to Maintain Haemoglobin Levels With Less Frequent Dosing A pivotal study published today in the Lancet has shown that dialysis patients can be effectively switched from frequently dosed anaemia drugs to (...) |
| 2007-10-18: |
SemBioSys Confirms Commercially Viable Levels of Native APO AI in Safflower
Calgary, Canada ( PRN/ots ) - - Canadian Biotechnology Company has now Established Commercial Levels of Both Native Apo AI and Apo AI( Milano ) variant in Safflower Seed Lines SemBioSys Genetics Inc. ( TSX:SBS ), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular (...) |
| 2007-10-18: |
NEJM Report Finds HPV Test More Effective Than Pap in Determining Cervical Cancer Risk
Gaithersburg, Maryland and Hilden, Germany ( PRN/ots ) - The first randomized, controlled study in North America of HPV testing as a stand - alone screen concluded that it is almost 40 percent more accurate than traditional cytology ( the Pap "smear" ) in identifying women with advanced cervical (...) |
| 2007-10-17: |
FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia
Philadelphia ( PRN/ots ) - At the U.S. Food and Drug Administration's ( FDA's ) Cardiovascular and Renal Drugs Advisory Committee meeting today, the majority of members voted to recommend the use of phosphate binders, including Shire Pharmaceuticals' non - calcium FOSRENOL( R ) ( lanthanum carbonate ), to treat hyperphosphatemia ( elevated (...) |
| 2007-10-15: |
Valdoxan( R ), the First Melatonergic Antidepressant, Confirms its Efficacy in Preventing Relapse Whatever the Severity of the Depression
Vienna, Austria ( PRN/ots ) - Valdoxan( R ) ( agomelatine ), the first melatonergic antidepressant, is an effective, long - term treatment for Major Depressive Disorder ( MDD ) according to new data presented today at the European College of Neurospsychopharmacology ( ECNP ) annual congress. The new international study showed Valdoxan's efficacy in preventing (...) |
| 2007-10-11: |
Micropill Belara® improves impure skin
Paris ( na Originaltextservice ) - At this year's 7th congress of the European Society of Gynaecology ( Paris, 10 - 14 October 2007 ), the German pharmaceutical company Grunenthal GmbH presents the latest study results for its oral contraceptive Belara®. As the first of its kind the (...) |
| 2007-10-10: |
MacroChem Announces Preferred Stock Conversions and US$3.5 Million Private Placement
Wellesley Hills, Massachusetts ( PRN/ots ) - MacroChem Corporation ( OTC Bulletin Board: MACM ) announced today that all the holders of its Series C Preferred Stock have converted their shares of preferred stock into 12,571,850 shares of common stock, and the warrants to purchase 8,648,102 (...) |
| 2007-10-10: |
MacroChem Announces Preferred Stock Conversions and US$3.5 Million Private Placement
Wellesley Hills, Massachusetts ( PRN/ots ) - MacroChem Corporation ( OTC Bulletin Board: MACM ) announced today that all the holders of its Series C Preferred Stock have converted their shares of preferred stock into 12,571,850 shares of common stock, and the warrants to purchase 8,648,102 (...) |
| 2007-10-10: |
New Survey Conveys Fundamental Shift in the Perceptions of Treatment Outcomes in Schizophrenia
Leuven, Belgium ( PRN/ots ) - - EUFAMI Survey Shows Carers Across Europe Believe in Remission as a Realistic Treatment Goal for Many People Living With Schizophrenia A large majority of families who care for someone with schizophrenia are confident that many people with (...) |
| 2007-10-05: |
Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
Collegeville, Pennsylvania ( PRN/ots ) - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announced today the signing of a definitive agreement under which it has acquired Haptogen Ltd., a Scottish company based in Aberdeen that is focused on the discovery of biopharmaceutical therapies. (...) |
|
|
back...
1
2
3
4
5
6
7
8
9
10
11
more... |
